<DOC>
	<DOCNO>NCT01126866</DOCNO>
	<brief_summary>The purpose clinical trial primarily assess efficacy intensify chemotherapy consist combination FOLFOXIRI + bevacizumab . The main focus lay rate patient achieve secondary complete ( R0 ) -resectable metastasis . The FOLFIRI + bevacizumab well FOLFOXIRI regimens show previously effective treatment advance CRC manageable toxicity . Therefore , intensify chemotherapy combine two standard regimen might promise therapeutic approach improve treatment metastatic disease outcome CRC . Patients advance colorectal carcinoma UICC stage IV , liver and/or lung metasta¬ses , optimally resectable , enrol single-arm phase II study . A minimum 4 cycle ( =8 week ) chemo¬therapy prior surgery mandatory patient . However , patient may withdraw study time upon request . Treatment preoperative chemothera¬py continue 2-4 week prior surgery last application bevacizumab ( FOLFOXIRI ) 4 week surgery , long 16 cycle ( = 32 week ) candidate eli¬gible surgery . Treatment discontinue prematurely disease progression unacceptable toxicity . As secondary endpoint acute perioperative toxi¬city preoperative chemotherapy accord NCI CTCAE v 3.0 include peri-and post-surgical complication well progression free survival overall survival quality life assess .</brief_summary>
	<brief_title>Curative Resectability Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma ( CRC ) Under Intensified Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Indication : Histologically confirm advanced colorectal carcinoma UICC Stages IV liver and/or lung metastasis , optimally resectable Measurable disease accord RECIST criterion . In case liver metastasis : 70 % liver replacement and/or &gt; 6 segment tumor involve , and/or involvement three hepatic vein , and/or involvement right leave portal pedicle , and/ involvement vena cava . In case lung metastasis : No tumor direct infiltration myocardium , esophagus , spine intrapericardial large vessel . Preoperative data indicate significant loss pulmonary function pulmonary metastasectomy severe impairment quality life . 3 . ECOG performance status &lt; 2 . 4 . Life expectancy &gt; 3 month 5 . Laboratory parameter : Proteinuria baseline : Patients proteinuria &lt; 2+ dipstick urinalysis . Patients 2+ proteinuria dipstick urinalysis baseline undergo 24h urine collection must proteinuria &lt; = 1 g protein/24 h. The required laboratory value baseline follow : Hematology : Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Hemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) International Normalized Ratio ( INR ) &lt; 1.5 ; aPTT &lt; 1.5 x ULN Biochemistry : Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST , ALT &lt; 2.5 x ULN patient without liver metastasis ; &lt; 5 x ULN patient liver metastasis Serum creatinine &lt; 2.0 mg/dL 177 ƒÝmol/L 6 . Willingness give write informed consent , write consent data protection willingness participate comply study . 1 . Past current history malignancy colorectal carcinoma . Patients curatively treat basal squamous cell carcinoma skin and/or insitu carcinoma cervix eligible . 2 . Previous chemotherapy ( except adjuvant chemotherapy ) . 3 . Extrahepatic and/or extrapulmonary metastasis except initially remove lymph node metastasis . 4 . History evidence upon physical examination CNS disease unless adequately treat ( e.g. , seizure control standard medical therapy history stroke ) . 5 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start ( wound heal complete ) , anticipation need major surgical procedure course study . 6 . Evidence bleed diathesis coagulopathy 7 . Serious , nonhealing wound , ulcer , bone fracture 8 . Treatment investigational agent participation clinical trial within 30 day study entry . 9 . Clinically significant ( i.e . active ) cardiovascular disease , e.g. , uncontrolled hypertension , cerebrovascular accident ( . 6 month prior treatment start ) , myocardial infarction ( . 6 month prior treatment start ) , unstable angina , New York Heart Association ( NYHA ) grade . II , congestive heart failure , serious cardiac arrhythmia require medication . 10 . Current recent serious polyneuropathy ( grade . 1 accord NCI CTCAE v3.0 criterion ; exception : absence tendon reflex ) 11 . Hematopoietic disease . 12 . Known intraabdominal inflammatory process serious gastrointestinal ulceration . 13 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 14 . Thromboembolic event severe hemorrhage ( `` T 6 month treatment start ) . 15 . Known hypersensitivity oxaliplatin , background medication ( bevacizumab , FA 5FU ) compound , incl . Chinese hamster ovary ( CHO ) cell proteins recombinant human humanize antibody . 16 . Known GilbertSyndrome 17 . Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational regimen patient high risk treatment complication 18 . As follow medication ( ) interactive effect may interfere patient 's ability meet study requirement , administer clinical study : sorivudine analog compound . Current recent ( within 10 day first dose study treatment ) treatment fulldose oral parenteral anticoagulant thrombolytic agent ( e.g. , marcumar therapy ) therapeutic purpose . Current recent ( within 10 day first dose study treatment ) chronic use aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) . 19 . Women , lactate , pregnant childbearing potential fertile men use highly effective contraceptive method1 . [ Women childbearing potential must negative pregnancy test ( serum bHCG ) within 7 day first dose study drug ] . 20 . Patients confine order either judicial administrative authority ( accord ¡± 40 Abs . 1 S. 3 AMG ) . 21 . Patients incapable understand aim , importance consequence study give legal inform consent ( accord ¡± 40 Abs . 4 ¡± 41 Abs . 2 Abs . 3 AMG ) . 22 . Patients history psychological illness condition interfere patient 's ability understand requirement study . 23 . Patients possibly dependent sponsor investigator . 24 . Patients participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>advanced colorectal carcinoma</keyword>
	<keyword>CRC</keyword>
	<keyword>UICC Stages IV</keyword>
	<keyword>liver and/or lung metastasis</keyword>
</DOC>